RxDoctor Payments Data

Cheryl Macdonald, MD

Family Medicine · Valley, NENPI 1700993433

Payments from drug & device makers

$1,408in general payments, 2019–2025

Across 92 payments — averaging $15.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$198
  • AstraZeneca$189
  • Novo Nordisk$143
  • AbbVie$128
  • Amgen$92
  • Novartis$86
  • plus $571 from 20 others

What the payments were for

  • Food & beverage$1,408100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,408 in reported general payments places this provider in the 65th percentile of 981 family medicine providers in Nebraska.

See all family medicine providers in Nebraska

Medicare billing

Part B allowed, 2024
$137,132
Medicare patients
255
Services billed
3,887

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin77$95,584
EliquisApixaban84$92,674
OzempicSemaglutide43$38,987
XareltoRivaroxaban24$28,899
MounjaroTirzepatide15$16,883
Tresiba Flextouch U-100Insulin Degludec20$14,034
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$13,431
Tresiba Flextouch U-200Insulin Degludec13$13,078
RestasisCyclosporine13$10,603
LinzessLinaclotide11$9,518
MyrbetriqMirabegron12$9,198
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$8,921
Breo ElliptaFluticasone/Vilanterol15$8,278
Humalog Kwikpen U-100Insulin Lispro21$6,789
GemtesaVibegron12$6,048

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$45$97,16495 claims
Boehringer IngelheimJardiance$198$95,58477 claims
Novo NordiskOzempic$143$38,98743 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$12$30,63041 claims
Johnson & JohnsonXarelto$29$28,89924 claims
AbbVieRestasis, Linzess, Synthroid$128$21,93554 claims
Lilly USA, LLCMounjaro$78$16,88315 claims
Astellas Pharma US IncMyrbetriq$31$9,19812 claims
AstraZenecaSymbicort$189$5,05115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 981 family medicine providers in Nebraska.

Other family medicine in Valley

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →